Belotecan in ovarian cancer anti-inflammatory potential and mechanistic insight to nano-formulations

IF 4.5 Q2 PHARMACOLOGY & PHARMACY

Future Journal of Pharmaceutical Sciences Pub Date : 2026-02-13 DOI:10.1186/s43094-026-00940-9

Ajay Kumar, Gesu Singla, Amita, Brahmjot Singh, Pooja Sharma, Sandeep Kaur, Poonam Chaturvedi, Bunty Sharma, Shafiul Haque, Hardeep Singh Tuli

{"title":"Belotecan in ovarian cancer anti-inflammatory potential and mechanistic insight to nano-formulations","authors":"Ajay Kumar, Gesu Singla,  Amita, Brahmjot Singh, Pooja Sharma, Sandeep Kaur, Poonam Chaturvedi, Bunty Sharma, Shafiul Haque, Hardeep Singh Tuli","doi":"10.1186/s43094-026-00940-9","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Ovarian cancer is a major gynecologic malignancy with high morbidity and mortality rates. Current treatment options have limited long-term effectiveness due to tumor resistance and significant side effects.</p><h3>Main body</h3><p>This article explores the potential of belotecan, a derivative of camptothecin, as a promising therapeutic agent for ovarian cancer. Belotecan’s ability to inhibit topoisomerase I, induce DNA damage, and modulate inflammation positions it as a strong candidate for enhancing ovarian cancer treatment. However, challenges such as poor bioavailability, rapid systemic clearance, and dose-limiting toxicity remain. To overcome these issues, nano-formulation strategies are proposed to improve pharmacokinetics, solubility, and tumor-specific targeting. These strategies may enhance belotecan's stability, increase its therapeutic efficacy, and minimize off-target effects.</p><h3>Conclusion</h3><p>This review provides a detailed examination of belotecan’s molecular mechanisms, its anti-inflammatory and anti-cancer properties, and the advances in nano-formulation technologies. The integration of these strategies could lead to more effective treatments and improved outcomes for ovarian cancer patients.</p><h3>Graphical abstract</h3>\n<div><figure><div><div><picture><source><img></source></picture></div></div></figure></div></div>","PeriodicalId":577,"journal":{"name":"Future Journal of Pharmaceutical Sciences","volume":"12 1","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2026-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://link.springer.com/content/pdf/10.1186/s43094-026-00940-9.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future Journal of Pharmaceutical Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43094-026-00940-9","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Ovarian cancer is a major gynecologic malignancy with high morbidity and mortality rates. Current treatment options have limited long-term effectiveness due to tumor resistance and significant side effects.

Main body

This article explores the potential of belotecan, a derivative of camptothecin, as a promising therapeutic agent for ovarian cancer. Belotecan’s ability to inhibit topoisomerase I, induce DNA damage, and modulate inflammation positions it as a strong candidate for enhancing ovarian cancer treatment. However, challenges such as poor bioavailability, rapid systemic clearance, and dose-limiting toxicity remain. To overcome these issues, nano-formulation strategies are proposed to improve pharmacokinetics, solubility, and tumor-specific targeting. These strategies may enhance belotecan's stability, increase its therapeutic efficacy, and minimize off-target effects.

Conclusion

This review provides a detailed examination of belotecan’s molecular mechanisms, its anti-inflammatory and anti-cancer properties, and the advances in nano-formulation technologies. The integration of these strategies could lead to more effective treatments and improved outcomes for ovarian cancer patients.

Graphical abstract

查看原文本刊更多论文

贝洛替康在卵巢癌抗炎潜能和纳米制剂的机制洞察

背景：卵巢癌是一种主要的妇科恶性肿瘤，发病率和死亡率都很高。目前的治疗方案由于肿瘤耐药性和显著的副作用，长期疗效有限。摘要本文探讨喜树碱衍生物贝洛替康作为卵巢癌治疗药物的潜力。Belotecan抑制拓扑异构酶I、诱导DNA损伤和调节炎症的能力使其成为加强卵巢癌治疗的有力候选药物。然而，诸如低生物利用度、快速全身清除和剂量限制性毒性等挑战仍然存在。为了克服这些问题，提出了纳米制剂策略来改善药代动力学，溶解度和肿瘤特异性靶向。这些策略可以增强贝洛替康的稳定性，提高其治疗效果，并尽量减少脱靶效应。本文综述了贝洛替康的分子机制、抗炎抗癌特性以及纳米制剂技术的研究进展。这些策略的整合可以为卵巢癌患者带来更有效的治疗和改善的结果。图形抽象

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Future Journal of Pharmaceutical Sciences PHARMACOLOGY & PHARMACY-

自引率

0.00%

发文量

审稿时长

23 weeks

期刊介绍： Future Journal of Pharmaceutical Sciences (FJPS) is the official journal of the Future University in Egypt. It is a peer-reviewed, open access journal which publishes original research articles, review articles and case studies on all aspects of pharmaceutical sciences and technologies, pharmacy practice and related clinical aspects, and pharmacy education. The journal publishes articles covering developments in drug absorption and metabolism, pharmacokinetics and dynamics, drug delivery systems, drug targeting and nano-technology. It also covers development of new systems, methods and techniques in pharmacy education and practice. The scope of the journal also extends to cover advancements in toxicology, cell and molecular biology, biomedical research, clinical and pharmaceutical microbiology, pharmaceutical biotechnology, medicinal chemistry, phytochemistry and nutraceuticals.